Wave Life Sciences Receives Positive Opinion for Orphan Drug Designation in the European Union for WVE-210201
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: GlobeNewswire
Investigational WVE-210201 in development for treatment of Duchenne muscular dystrophy patients amenable to exon 51 skipping Patients currently enrolling in global Phase 1 clinical trial CAMBRIDGE, Mass., July 02, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) issued a positive opinion recommending WVE-210201 for designation as an orphan medicinal product for the treatment of Duchenne muscular dystrophy (DMD). “This positive opinion from the EMA’s Committee for Orphan Medical Products, based on our in vivo data supporting medical plausibility and the potential for significant benefit of WVE-210201, marks another milestone in our efforts to try to improve the lives of boys suffering from Duchenne muscular dystrophy,” said Michael Panzara
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Ltd. (NASDAQ: WVE) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $17.00 price target on the stock.MarketBeat
- Wave Life Sciences to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences to Present at Upcoming Investor ConferencesGlobeNewswire
- Wave Life Sciences Ltd. (NASDAQ:WVE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]Yahoo! Finance
WVE
Earnings
- 3/6/24 - Beat
WVE
Sec Filings
- 4/5/24 - Form 4
- 4/3/24 - Form 144
- 3/6/24 - Form 10-K
- WVE's page on the SEC website